New Drug Mitapivat Shows Positive Phase 3 Results for Sickle Cell Disease

Agios Pharmaceuticals announced encouraging Phase 3 trial data for its drug, mitapivat, in treating sickle cell disease. The study demonstrated significant improvements in hemoglobin levels and a notable reduction in the need for blood transfusions among patients. The medication was also reported to be well-tolerated, suggesting a promising new treatment option.